Intrinsiqq
Viracta Therapeutics, Inc. logo

Viracta Therapeutics, Inc.

VIRX

Compare

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$43M

▼ -3.8% YoY

Op. Margin

–

ROIC

-89.58%

▼ -18.6pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$35M

▼ -12.8% YoY

Op. Cash Flow (TTM)

-$35M

▼ -12.5% YoY

Net Debt

$13M

Cash & Equiv.

$21M

5Y CAGR: -47.7%

Continue Research

SourceComputed from the 10-Q filed 11 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.

Peers

Pharmaceutical Preparations · Pick stocks to compare with VIRX

CompareIntrinsic value
ABBVAbbVie Inc.
$286.20+0.94%49
SKVISkinvisible Inc.
$0.18+0.00%0
SILOSilo Pharma Inc.
$1.73-7.98%10
CAMPCamp4 Therapeutics Corp.
$3.79-5.25%40
RANIRani Therapeutics Holdings Inc.
$0.51-12.03%10
HYPDHyperion DeFi, Inc.
$2.08-11.11%50
SERSerina Therapeutics Inc.
$1.12-6.67%40
DAREDare Bioscience Inc.
$0.41-9.96%10

Spot a number that looks wrong? Check it in VIRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing VIRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.